CRL at a glance
Charles River Laboratories (CRL, SEC CIK 1100682) filed its latest 10-K annual report on February 18, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 9, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 27, 2025 (FY2025), Charles River Laboratories (CRL) reported revenue of $4.0 billion (down 0.9% from FY2024) and a net loss of $144.3 million. Diluted EPS was -$2.91.
- As of September 30, 2026, 34 institutional investment managers tracked by SignalX reported holding Charles River Laboratories (CRL) shares worth $6.6 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by FOSTER JAMES C on October 22, 2026 of 24,042 shares at $350.00 per share.
- In the last 90 days, CRL insiders reported 1 open-market purchase ($3K) and 4 open-market sales ($19.5M) on Form 4, a net sale of $19.5M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $4.0B
- −0.9% vs prior year
- Insiders · 90 days
- 1 buy · 4 sells
- Net −$19.5M
- 13F holders
- 34 funds
- $6.6B · +0 vs prior quarter
- Latest 8-K
- Nov 9, 2026
- Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 27, 2025
Management Discussion & Analysis
- Revenue DSA declined in fiscal 2025 due to lower study volumes; RMS revenue increased driven by large research models and pricing; Manufacturing Microbial Solutions grew robustly
- Goodwill impairment of $165M in Biologics Solutions for 2025 due to reduced performance; impairment $215M in 2024 in same unit
- Best segment: Manufacturing Microbial Solutions with robust growth, share gains, and higher sales; Worst segment: DSA with declined revenue and backlog falling to $1.9B from $2.0B
- Capital allocation: Acquired KF for $510M, Noveprim controlling interest for $392.4M, SAMDI for $62.8M, PathoQuest option for ~$60M; acquisitions funded by cash and Credit Facility
- Forward outlook: $300M cost savings by 2026; focus on strategic acquisitions, partnerships, and divestments of 7% 2025 revenue; cautious early-stage R&D spending remains a risk
Business Overview
- Core business model: Preclinical and clinical laboratory services for drug discovery and development
- No new products, services, or business segments introduced or emphasized in this fiscal year
- Maintained existing strategic practices, including strict compliance on timing of equity awards and insider trading policies
- Fiscal 2025 equity awards policy with no stock options granted near earnings releases to avoid insider trading risks
- No errors or clawbacks of executive compensation reported during or after fiscal 2025
Risk Factors
- Cybersecurity risk governance by Board Audit Committee with quarterly reviews and direct CIO, CISO reporting to Audit Chair
- Heavy reliance on Chief Information Officer with 30+ years experience for global IT risk oversight and digital strategy execution
- Cybersecurity assessments include third-party audits, vulnerability tests, and industry standard compliance frameworks
- Incident Response Plan mandates escalation to Audit Committee for significant cybersecurity events
- No specific regulatory, geopolitical, operational supply chain, competitive, or financial risks detailed in this section
AI summary of the CRL 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 26, 2026
Risk Factors
- No material changes to 2025 Form 10-K risk factors
- Q1 10-Q risk factor incorporated by reference, with no details repeated this quarter
- Additional unknown or currently immaterial risks could materially adversely affect results
Management Discussion & Analysis
- Quarterly revenue $982.7M, down $22.1M or 2.2% YoY
- Operating margin 20.6% vs 13.3% YoY, operating income $202.6M vs $133.8M
- Best segment: Manufacturing revenue $178.9M, operating margin 35.7% vs 20.9%
- Worst segment: RMS revenue $207.5M, down 2.8% YoY, driven by Cell Solutions divestiture
- Cash $200.4M vs $213.8M, operating cash flow $474.9M vs $590.1M, $300.0M stock repurchases and $467.3M acquisitions through nine months
AI summary of the CRL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Acquisition agreement for Frontage Holdings’ bioanalysis and DMPK operations in Exton, Pennsylvania
- Expands Charles River’s drug-development services footprint through added bioanalysis and DMPK capabilities
Item EX-99.1: Item EX-99.1
- Acquisition price approximately $470 million cash, plus up to $75 million performance-based payments
- Target includes Frontage’s Exton, Pennsylvania bioanalysis and DMPK operations, two sites, approximately 340 employees
Item 2.02: Results of Operations and Financial Condition
- Q3 fiscal 2026 financial results released for the period ended September 26, 2026
- Investors should review Exhibit 99.1 for revenue, earnings, guidance and operating drivers
Item EX-99.1: Item EX-99.1
- Q3 revenue $982.7M, down 2.2% reported but organic growth 4.7%, signaling underlying demand recovery after divestitures
- Non-GAAP EPS $3.09, up 27.2%, with operating margin expanding 330 basis points to 23.0%
Item 7.01: Regulation FD Disclosure
- Investor Day materials outline CRL’s business strategy and long-term financial targets through 2030
- Management reaffirmed full-year 2026 guidance, reducing near-term uncertainty around existing outlook
AI summaries of CRL 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CRL
Don't miss the next CRL filing
- Alerts as it files. A push when CRL files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CRL, by share count.
- Ask anything. An AI agent that reads every CRL filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Knell Michael Gunnar | F | Nov 6, 2026 | 649 | $313.02 |
| FOSTER JAMES C | Sell | Oct 22, 2026 | 24,042 | $350.00 |
| FOSTER JAMES C | M | Oct 22, 2026 | 24,042 | - |
| FOSTER JAMES C | M | Oct 22, 2026 | 24,042 | $244.41 |
| Parisotto Shannon M | M | Oct 21, 2026 | 2,156 | - |
| Parisotto Shannon M | M | Oct 21, 2026 | 2,156 | $244.41 |
| Parisotto Shannon M | Sell | Oct 21, 2026 | 2,156 | $344.41 |
| Parisotto Shannon M | M | Oct 5, 2026 | 981 | $208.44 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $4.1B | $4.0B | $4.0B |
| Operating Income | $617.3M | $227.3M | $25.2M |
| Net Income | $474.6M | $22.2M | -$144.3M |
| Op. Margin | 14.9% | 5.6% | 0.6% |
| Net Margin | 11.5% | 0.5% | -3.6% |
| Balance Sheet | |||
| Total Assets | $8.2B | $7.5B | $7.1B |
| Equity | - | $3.5B | $3.2B |
| ROE | - | 0.6% | -4.6% |
| Per Share | |||
| EPS | $9.22 | $0.20 | $-2.91 |
| Cash Flow | |||
| Operating CF | $683.9M | $734.6M | $737.6M |
Source: XBRL data in Charles River Laboratories (CRL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate CRL share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 34 | $6.57B |
| Q2 2026 | 34 | $6.49B |
| Q1 2026 | 36 | $4.72B |
| Q4 2025 | 35 | $4.76B |
| Q3 2025 | 35 | $3.30B |
| Q2 2025 | 32 | $2.98B |
| Q1 2025 | 31 | $2.48B |
| Q4 2024 | 30 | $2.54B |
- T. Rowe Price Group+1.50M (+100%)
- JPMorgan Chase & Co+151.3K (+53%)
- Morgan Stanley+86.5K (+11%)
- Principal Financial Group+16.2K (+31%)
- Prudential Financial+10.5K (+32%)
- Invesco Ltd−1.13M (-38%)
- Dimensional Fund Advisors−714.9K (-43%)
- Citadel Advisors LLC−690.5K (-58%)
- Ameriprise Financial−450.7K (-51%)
- Bank of America Corp−213.9K (-18%)
- FMR LLC (Fidelity)−4.24M
- Marex Group plc−2.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 267 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CRL filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 9, 2026 | - | - | - |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 10-Q | Nov 4, 2026 | Sep 26, 2026 | Analysis | |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 4 | Oct 26, 2026 | - | - | - |
| 4 | Oct 23, 2026 | - | - | - |
| 4 | Oct 7, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 8-K | Sep 24, 2026 | - | Analysis | - |
| 4 | Aug 27, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| SC 13G | Aug 13, 2026 | - | - | |
| 4 | Aug 11, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 4 | Aug 10, 2026 | - | - | - |
| 4 | Aug 10, 2026 | - | - | - |
| 4 | Aug 6, 2026 | - | - | - |
| 10-Q | Aug 5, 2026 | Jun 27, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jun 8, 2026 | - | - |
Related Health Care companies
- ABSI · Absci CorpServices-Commercial Physical & Biological Research
- INCY · IncyteServices-Commercial Physical & Biological Research
- IQV · IQVIAServices-Commercial Physical & Biological Research
- MXCT · MAXCYTE, INC.Services-Commercial Physical & Biological Research
- MEDP · Medpace Holdings IncServices-Commercial Physical & Biological Research
- NRC · NATIONAL RESEARCH CORPServices-Commercial Physical & Biological Research
- OABI · OmniAb, Inc.Services-Commercial Physical & Biological Research
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
CRL SEC filings: frequently asked questions
Are CRL insiders buying or selling?
In the last 90 days, Charles River Laboratories (CRL) officers, directors and 10% owners reported 1 open-market purchase worth $2,974 by 1 insider and 4 open-market sales worth $19.5 million by 2 insiders on Form 4, a net sale of $19.5 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CRL stock?
As of September 30, 2026, the largest Charles River Laboratories (CRL) holders among the 13F filers tracked by SignalX were BlackRock ($1.1 billion), Vanguard Capital Management LLC ($922.7 million), T. Rowe Price Group ($887.4 million), Vanguard Portfolio Management LLC ($645.8 million), State Street Corp ($552.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CRL's revenue in fiscal year 2025?
For the fiscal year ended December 27, 2025 (FY2025), Charles River Laboratories (CRL) reported revenue of $4.0 billion (down 0.9% from FY2024) and a net loss of $144.3 million. Diluted EPS was -$2.91. The figures come from the XBRL data in the 10-K.
What are the main risks in CRL's latest 10-K?
In the 10-K filed February 18, 2026, Charles River Laboratories (CRL) flagged: Cybersecurity risk governance by Board Audit Committee with quarterly reviews and direct CIO, CISO reporting to Audit Chair. Heavy reliance on Chief Information Officer with 30+ years experience for global IT risk oversight and digital strategy execution. (AI summary of the Risk Factors section.)
What did CRL report in its latest 8-K?
Charles River Laboratories (CRL) filed an 8-K on November 9, 2026 reporting Item 7.01 (Regulation FD Disclosure). Acquisition agreement for Frontage Holdings’ bioanalysis and DMPK operations in Exton, Pennsylvania.
What are the latest CRL SEC filings?
Charles River Laboratories (CRL) filed its latest 10-K annual report on February 18, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 9, 2026.
What is CRL's SEC CIK number?
Charles River Laboratories (CRL)'s SEC Central Index Key (CIK) is 1100682. EDGAR lists every CRL filing under that number.
Ask anything about CRL
The research agent reads CRL's filings, financials, insider trades and 13F holders, then answers with sources.